A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Clinical Trials
Hoffmann-La Roche
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
135 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St George Hospital
Kogarah, New South Wales, Australia
- Adelaide Cancer Centre
Kurralta Park, South Australia, Australia
- Peter Maccallum Cancer Center
North Melbourne, Victoria, Australia
- Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
- Clinique Ste-Elisabeth
Namur, Belgium
- Santa Casa de Misericordia de Salvador
Salvador, Estado de Bahia, Brazil
- Hospital Do Cancer de Pernambuco - Hcp
Recife, Pernambuco, Brazil
- Hospital Nossa Senhora Da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
- Hospital Sao Lucas - Pucrs
Porto Alegre, Rio Grande do Sul, Brazil
- Instituto Nacional de Cancer - Inca; Oncologia
Rio de Janeiro, Rio de Janeiro, Brazil
- Faculdade de Medicina Do Abc - Fmabc
Santo André, São Paulo, Brazil
- Instituto Do Cancer Do Estado de Sao Paulo - Icesp
São Paulo, São Paulo, Brazil
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Cancer Care Manitoba
Winnipeg, Manitoba, Canada
- London Health Sciences Centre
London, Ontario, Canada
- Beijing Cancer Hospital
Beijing, China
- West China Hospital, Sichuan University
Chengdu, China
- Fujian Cancer Hospital
Fuzhou, China
- Fudan University Shanghai Cancer Center
Shanghai, China
- Shanghai East Hospital
Shanghai, China
- Shanghai Ninth People'S Hospital Affiliated To Shanghai Jiao Tong University School of Medicine
Shanghai, China
- Tianjin Medical University General Hospital
Tianjin, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
- Zhejiang Cancer Hospital
Zhejiang, China
- Institut Sainte Catherine
Avignon, France
- Centre Georges Francois Leclerc
Dijon, France
- Centre Leon Berard; Département D?hématologie Et D?oncologie
Lyon, France
- Hopital Timone Adultes; Oncologie Medicale Et Usp
Marseille, France
- Icm; Radiotherapie
Montpellier, France
- Hopital Tenon; Oncologie Radiotherapie
Paris, France
- Chu Bordeaux
Pessac, France
- Hôpitaux D'Instruction Des Armees Begin
Saint-Mandé, France
- Gustave Roussy Cancer Campus; Radiotherapie
Villejuif, France
- Universitätsklinikum Bonn; Med. Klinik Und Poliklinik Iii; Hämatologie, Onkologie Und Rheumatologie
Bonn, Germany
- Universitätsklinikum Freiburg, Klinik Für Strahlenheilkunde
Freiburg im Breisgau, Germany
- Klinikum D. Uni. München; Campus Großhadern; Klinik Und Poliklinik F. Strahlenthera. Und Radioonko
München, Germany
- Universitätsmedizin Rostock, Klinik Und Poliklinik Für Strahlentherapie; Zentrum Für Radiologie
Rostock, Germany
- Budapesti Uzsoki Utcai Kórház
Budapest, Hungary
- Orszagos Onkologial Intezet; Onkologiai Osztaly X
Budapest, Hungary
- Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet
Pécs, Hungary
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Apr 2018
- Primary completion
- 27 Sept 2023
- Completion
- 6 Mar 2024
- Last update posted
- 9 Oct 2024
- Registered enrollment
- 406
- Registry id
- NCT03452137
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.